Compounds > tachyplesin peptide, tachypleus tridentatus
Page last updated: 2024-11-12

tachyplesin peptide, tachypleus tridentatus

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tachyplesin peptide, Tachypleus tridentatus: isolated from the hemocytes of the horseshoe crab (Tachypleus tridentatus); cationic peptide; 17 amino acid residues given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16129721
CHEMBL ID4544197
MeSH IDM0161144

Synonyms (11)

Synonym
tachyplesin
tachyplesin i (reduced), cyclic (3.16),(7.12)-bis(disulfide)
tachyplesin i
tachyplesin i (tachypleus tridentatus)
nh2-lys-trp-cys(x2)-phe-arg-val-cys(x1)-tyr-arg-gly-ile-cys(x1)-tyr-arg-arg-cys(x2)-arg-nh2
kwcfrvcyrgicyrrcr-nh2
118231-04-2
tachyplesin peptide, tachypleus tridentatus
CHEMBL4544197
CS-0065054
HY-P1632

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" With the developments of DNA microarray technology, the genetic analysis of the toxic effect of TP I on embryo was originally considered in our recent study."( Genomic and functional analysis of the toxic effect of tachyplesin I on the embryonic development of zebrafish.
Dai, J; Jin, G; Zhao, H, 2014)		0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
"We investigated the efficacy of Tachyplesin III alone or combined with piperacillin-tazobactam (TZP) to prevent biofilm formation in vitro and in a rat model of Pseudomonas aeruginosa ureteral stent infection."( The antimicrobial peptide tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model.
Cirioni, O; Ghiselli, R; Giacometti, A; Giovanni, M; Kamysz, E; Kamysz, W; Minardi, D; Orlando, F; Parri, G; Saba, V; Scalise, G; Silvestri, C, 2007)		0.34
"Aim of our study was to investigate the in vitro effects of Tachyplesin III (TP), a potent disulfide-linked peptide, in dermatophytes infections, with respect to or in combination with terbinafine (TERB), against 20 clinical isolates of dermatophytes belonging to four species."( In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes.
Arzeni, D; Barchiesi, F; Campanati, A; Cirioni, O; Gabrielli, E; Ganzetti, G; Giacometti, A; Kamysz, E; Kamysz, W; Lenci, I; Marconi, B; Offidani, A; Scalise, G; Silvestri, C; Simonetti, O, 2009)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1583641Antimicrobial activity against Klebsiella pneumoniae BAA 2470 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583652Bactericidal activity against Enterococcus faecium ATCC 292122020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583659Antimicrobial activity against Lysobacter enzymogenes YC36 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583656Cytotoxicity in human L02 cells assessed as reduction in cell viability at >64 ug/ml incubated for 48 hrs by resazurin dye based assay2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583655Cytotoxicity in human L02 cells assessed as reduction in cell viability at <32 ug/ml incubated for 48 hrs by resazurin dye based assay2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583640Antimicrobial activity against Klebsiella pneumoniae BAA 1144 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583644Antimicrobial activity against Acinetobacter baumannii ATCC 19606 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583633Toxicity in human erythrocytes assessed as induction of hemolysis incubated for 1 hr by visual absorption spectroscopy2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583662Antimicrobial activity against Lysobacter enzymogenes YC36 assessed as inhibition of visible growth measured after 7th generation exposure to compound by continuous repeated transfer assay relative to before passage2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583627Antimicrobial activity against Enterobacter cloacae BAA 1143 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583653Toxicity in human erythrocytes assessed as induction of hemolysis incubated for 1 hr by spectrometry2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583637Antimicrobial activity against Staphylococcus aureus ATCC 29213 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583654Toxicity in human erythrocytes assessed as induction of hemolysis at <50 ug/ml incubated for 1 hr by spectrometry2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583650Bactericidal activity against Lysobacter enzymogenes YC362020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583646Bactericidal activity against Escherichia coli K-122020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583634Stability in human plasma assessed as parent compound remaining at 20 mM measured after 2 hrs by HPLC analysis2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583632Antimicrobial activity against Escherichia coli K-12 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583639Antimicrobial activity against Staphylococcus aureus BAA 44 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583647Bactericidal activity against Staphylococcus aureus ATCC 292132020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583636Stability in human plasma assessed as parent compound degradation at 20 mM measured after 6 hrs by HPLC analysis2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583643Antimicrobial activity against Pseudomonas aeruginosa BAA 2108 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583630Antimicrobial activity against Escherichia coli ATCC 25923 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583638Antimicrobial activity against Staphylococcus aureus BAA 41 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583645Antimicrobial activity against Enterococcus faecium ATCC 29212 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583628Antimicrobial activity against Bacillus subtilis 168 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583629Bactericidal activity against Bacillus subtilis 1682020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583649Bactericidal activity against Shigella flexneri ATCC 299032020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583660Bactericidal activity against Lysobacter enzymogenes YC36 at 4 ug/ml2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583642Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583648Bactericidal activity against Pseudomonas aeruginosa ATCC 278532020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583631Antimicrobial activity against Escherichia coli BAA 2469 assessed as inhibition of visible growth incubated for 18 hrs2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID1583651Bactericidal activity against Acinetobacter baumannii ATCC 196062020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (135)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.48)18.7374
1990's46 (34.07)18.2507
2000's35 (25.93)29.6817
2010's41 (30.37)24.3611
2020's11 (8.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.23 (24.57)
Research Supply Index4.92 (2.92)
Research Growth Index6.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews17 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other119 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		2.0310halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
hydrochloric acid
Hydrochloric Acid: A strong corrosive acid that is commonly used as a laboratory reagent. It is formed by dissolving hydrogen chloride in water. GASTRIC ACID is the hydrochloric acid component of GASTRIC JUICE.. hydrogen chloride : A mononuclear parent hydride consisting of covalently bonded hydrogen and chlorine atoms.		1.9810chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride		mouse metabolite
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		1.9810sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
glycine
[no description available]		210alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
phenol
[no description available]		2.0110phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
phosphorylcholine
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.		2.420phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.0310aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		2.9140
nalidixic acid
[no description available]		1.98101,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
temozolomide
[no description available]		2.2110imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		2.4120alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		210aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		2.110kanamycinsbacterial metabolite
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		2.3920amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		1.9910amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		2.6930erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		210arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
dimethyl sulfate
dimethyl sulfate: RN given refers to unlabeled cpd; structure. dimethyl sulfate : The dimethyl ester of sulfuric acid.		1.9810alkyl sulfatealkylating agent;
immunosuppressive agent
penicillanic acid
Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed). penicillanic acid : A penam that consists of 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane bearing a carboxy group at position 2 and having (2S,5R)-configuration.		2.4420penicillanic acids
1-naphthylphenylamine
N-phenyl-1-naphthylamine: RN given refers to 1-naphthylamine cpd; structure		2.0110naphthalenes
cyclohexanol
Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.		2.0110cyclohexanols;
secondary alcohol		solvent
1-naphthylamine
1-Naphthylamine: A suspected industrial carcinogen (and listed as such by OSHA). Its N-hydroxy metabolite is strongly carcinogenic and mutagenic.. naphthylamine : A primary arylamine that is naphthalene substituted by an amino group at unspecified position.. 1-naphthylamine : A naphthylamine that is naphthalene substituted by an amino group at position 1.		2.0110naphthylaminehuman xenobiotic metabolite
dithiothreitol
1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.		1.98101,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent
barium chloride
barium chloride: RN given refers to parent cpd. barium chloride : The inorganic dichloride salt of barium.		2.0310barium salt;
inorganic chloride		potassium channel blocker
amikacin
Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.		2.1310alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		2.4420penicillin allergen;
penicillin		antibacterial drug
cefoperazone
Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.		2.1310cephalosporinantibacterial drug
plerixafor
plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.		1.9910azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
fluorexon
fluorexon: structure		2.6930xanthene dyefluorochrome
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.06101,2,3-triazole
6-carboxyfluorescein
6-carboxyfluorescein: originally sold as 6-carboxyfluorescein, but commercial product is a mixture of two isomers; correct name is 5(6)-carboxyfluorescein		1.9810monocarboxylic acid
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		2.0410macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
fibrinogen
Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.		2.0210iditolfungal metabolite
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.0310beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
tazobactam
Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.		2.0410penicillanic acids;
triazoles		antiinfective agent;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
carbapenems
[no description available]		3.3510
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		1.9810heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
dodecylphosphocholine
dodecylphosphocholine: phospholipase A2 inhibitor; RN refers to chloride. dodecylphosphocholine : A phosphocholine that is the monododecyl ester of phosphocholine		2.420phosphocholinesdetergent
terbinafine
[no description available]		2.0510acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
cystine
[no description available]		2.6930
led209
LED209: structure in first source		2.2510
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		3.1450cysteiniumfundamental metabolite
mastoparan
[no description available]		3.5820mastoparans;
peptidyl amide		antimicrobial agent
melitten
Melitten: Basic polypeptide from the venom of the honey bee (Apis mellifera). It contains 26 amino acids, has cytolytic properties, causes contracture of muscle, releases histamine, and disrupts surface tension, probably due to lysis of cell and mitochondrial membranes.		3.7830
t22 protein, synthetic
T22 protein, synthetic: a synthetic protein with anti-human immunodeficiency virus activity; do not confuse with T22 antigen, a class I histocompatibility antigen		3.2460
magainin 2 peptide, xenopus
magainin 2 peptide, Xenopus: from skin of Xenopus laevis; 23-amino acid sequence given in first source; differs from magainin 1 by substitution of Lys instead of Gly at position 10 & Asn instead of Lys at position 22; also used to prevent development of malarial oocysts in mosquito vector; Z-12 is magainin 2 with Lys and Phe residues replaced with their respective D-isomers; homologue of the Xenopus laevis cement; GenBank AF004262 (mouse), AF007791, AF038451-2 (human)		4.8660
t140 peptide
T140 peptide: a strong anti-hiv agent; amino acid sequence in first source		1.9910
cecropin p1-li
cecropin P1-LI: antibacterial peptide isolated from porcine intestine; has immunoreactivity in epithelial cells of duodenum & glucagon cells of the pancreas		1.9910
protegrin-5
protegrin-5: GenBank X84096		1.9910
protegrin-1
protegrin-1: GenBank X84094		4.3660
alamethicin
Alamethicin: A cyclic nonadecapeptide antibiotic that can act as an ionophore and is produced by strains of Trichoderma viride. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		3.4920
magainin 1 peptide, xenopus
magainin I: Antibiotic peptide. Thought to preferentially bind to anionic phosholipids.		3.110
pexiganan
[no description available]		2.4420
gramicidin a
Gramicidin: A group of peptide antibiotics from BACILLUS brevis. Gramicidin C or S is a cyclic, ten-amino acid polypeptide and gramicidins A, B, D are linear. Gramicidin is one of the two principal components of TYROTHRICIN.		2.3920
ceca1 protein, drosophila
[no description available]		3.0810
magainin a
magainin A: RN from CA Index Guide		3.0810
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		2.4201,2-diacyl-sn-glycero-3-phosphocholine
piperacillin, tazobactam drug combination
Piperacillin, Tazobactam Drug Combination: An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS.		2.0310
alx40 4c
N-alpha-acetyl-nona-D-arginine amide acetate: inhibits HIV-1 by acting as competitive inhibitor of HIV Tat protein; cxcr4 receptor antagonist; structure in first source		1.9910
colistin
Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.		2.4820
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		1.9810carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
mastoparan x
mastoparan X: RN given refers to the all-(L)-isomer. mastoparan-V : A member of the class of mastopyrans that is a 14-amino acid polypeptide comprising isoleucyl, asparaginyl, tryptophyl, lysyl, glycyl, isoleucyl, alanyl, alanyl, methionyl, alanyl, lysyl, lysyl, leucyl, and leucinamide residues coupled in sequence. It is the major active component of the venom of the hornet Vespa velutina and causes degranulation of mast cells. It exhibits antimicrobial activity against both Gram-positive and -negative bacteria as well as haemolytic activity on chicken, human and sheep erythrocytes.		3.0910mastoparans;
peptidyl amide		antibacterial agent
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor		2.0310
clavanin a
clavanin A: histidine-rich, amidated, alpha-helical protein isolated from the hemocytes of Styela clava; amino acid sequence in first source		2.4220
crambin protein, crambe abyssinica
crambin protein, Crambe abyssinica: 44 amino acid, molecular weight 5000, water-insoluble protein found in the seed of the plant Crambe abyssinica		1.9810
muramidase
Muramidase: A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17.		2.0810
gallidermin
gallidermin: lanthionine-containing peptide antibiotic (lantibiotic); from Staphylococcus gallinarum; structure given in first source		210
temporin
temporin: isolated from frogs Rana temporaria & R. clamitans; has many isoforms; amino acid sequence in first source		2.1510
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Disease
[description not available]		02.3110
Bacterial Infections
Infections by bacteria, general or unspecified.		02.3110
Koch's Disease
[description not available]		02.4110
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		02.4110
Co-infection
[description not available]		02.4110
Infections, Staphylococcal
[description not available]		02.4110
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.4110
Benign Neoplasms
[description not available]		05.3850
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		05.3850
Benign Neoplasms, Brain
[description not available]		02.2110
Astrocytoma, Grade IV
[description not available]		02.5820
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.2110
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.5820
Acinetobacter Infections
Infections with bacteria of the genus ACINETOBACTER.		03.1710
Carcinoma, Non-Small Cell Lung
[description not available]		02.3110
Cancer of Lung
[description not available]		02.6120
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.3110
Lung Neoplasms
Tumors or cancer of the LUNG.		02.6120
Black Fever
[description not available]		02.3110
Leishmaniasis, Visceral
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.		02.3110
Extravascular Hemolysis
[description not available]		03.6390
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		03.6390
Lung Adenocarcinoma
[description not available]		02.1510
Adenocarcinoma, Basal Cell
[description not available]		02.4720
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		02.1510
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.4720
Blood Clot
[description not available]		02.2110
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		02.2110
Glial Cell Tumors
[description not available]		02.5320
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.5320
Disease Resistance
The capacity of an organism to defend itself against pathological processes or the agents of those processes. This most often involves innate immunity whereby the organism responds to pathogens in a generic way. The term disease resistance is used most frequently when referring to plants.		02.110
Blood Poisoning
[description not available]		02.4420
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.9440
E coli Infections
[description not available]		02.0410
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.0410
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.4420
Dermatomycoses
Superficial infections of the skin or its appendages by any of various fungi.		02.0510
Hepatocellular Carcinoma
[description not available]		02.730
Cancer of Liver
[description not available]		02.730
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.730
Liver Neoplasms
Tumors or cancer of the LIVER.		02.730
Bladder Cancer
[description not available]		02.0210
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		02.0210
Cancer of Stomach
[description not available]		02.0310
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.0310
Infections, Pseudomonas
[description not available]		02.4420
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		02.4420
Ureteral Diseases
Pathological processes involving the URETERS.		02.0310
Primary Peritonitis
[description not available]		02.0410
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		02.4220
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		02.0410
Infection
[description not available]		02.9110
Infections
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.		02.9110
Parodontosis
[description not available]		02.9110
Periodontal Diseases
Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.		02.9110
HIV Coinfection
[description not available]		0210
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		0210
B16 Melanoma
[description not available]		0210
Cancer of Prostate
[description not available]		0210
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		0210
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.3820
Pyrexia
[description not available]		01.9710
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		01.9710